A team of University of Alberta researchers has developed a cardio-oncology drug that protects the heart from chemotherapy damage while enhancing the effectiveness of cancer treatments against tumor growth and spread. In a paper published as the cover story in Science Translational Medicine, the team identifies the target protein ZNF281 and a new drug they've developed called ZIM, or ZNF281 Interfering Molecule.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗